Profile data is unavailable for this security.
About the company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
- Revenue in USD (TTM)0.00
- Net income in USD-93.97m
- Incorporated2017
- Employees55.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 466.25m | 100.00 | -- | 5.11 | -- | 5.51 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -264.41m | 469.10m | 130.00 | -- | 0.8949 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| OmniAB Inc | 20.41m | -63.02m | 471.27m | 106.00 | -- | 1.71 | -- | 23.09 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Regenxbio Inc | 84.33m | -238.81m | 475.14m | 344.00 | -- | 1.57 | -- | 5.63 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 479.58m | 38.00 | -- | 569.13 | -- | 10.00 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 482.30m | 49.00 | -- | 2.50 | -- | -- | -- | -- | -- | 3.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0039 | -- | -- | -- | -58.47 | -- | -- | -- |
| Celcuity Inc | 0.00 | -93.97m | 489.74m | 55.00 | -- | 3.45 | -- | -- | -2.61 | -2.61 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -45.24 | -37.32 | -49.93 | -39.16 | -- | -- | -- | -- | -- | -- | 0.393 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Korro Bio Inc | 0.00 | -101.60m | 490.05m | 95.00 | -- | 2.70 | -- | -- | -17.04 | -17.04 | 0.00 | 19.28 | 0.00 | -- | -- | 0.00 | -70.10 | -31.55 | -76.20 | -36.48 | -- | -- | -- | -365.87 | -- | -104.93 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -88.07m | 491.80m | 66.00 | -- | 1.35 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| ProKidney Corp | 0.00 | -45.61m | 492.91m | 163.00 | -- | -- | -- | -- | -0.5541 | -0.5541 | 0.00 | -3.36 | 0.00 | -- | -- | 0.00 | -29.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 498.18m | 150.00 | -- | 2.51 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Zenas Biopharma Inc | 0.00 | -128.97m | 501.49m | 115.00 | -- | 1.31 | -- | -- | -3.19 | -3.19 | 0.00 | 8.60 | 0.00 | -- | -- | 0.00 | -52.94 | -- | -60.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -122.68m | 503.08m | 87.00 | -- | 2.57 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 506.21m | 52.00 | -- | 6.67 | -- | 51.05 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Sep 2024 | 3.47m | 9.36% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 2.36m | 6.38% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 1.87m | 5.06% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.68m | 4.53% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.57m | 4.25% |
| Eventide Asset Management LLCas of 30 Sep 2024 | 1.54m | 4.15% |
| Commodore Capital LPas of 30 Sep 2024 | 1.52m | 4.11% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 1.30m | 3.52% |
| Samlyn Capital LLCas of 30 Sep 2024 | 1.29m | 3.49% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2024 | 1.25m | 3.36% |
